Kisqali

Ribociclib, the active ingredient in Kisqali, is a CDK4/6 inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive, HER2‑negative advanced or metastatic breast cancer in adult patients.

GNH USA supplies Kisqali as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Kisqali is a targeted therapy used in the hormone receptor‑positive, HER2‑negative breast cancer pathway.

Hormone receptor‑positive, HER2‑negative advanced breast cancer: delays disease progression and extends progression‑free survival. Hormone receptor‑positive, HER2‑negative metastatic breast cancer: improves progression‑free survival when combined with endocrine therapy. HR‑positive, HER2‑negative breast cancer in combination with endocrine agents: enhances overall treatment efficacy.

Common Side Effects: - Neutropenia: reduced white blood cell count. - Nausea and vomiting. - Fatigue and asthenia. - Diarrhea. - Alopecia: hair thinning or loss. - Elevated liver enzymes.

Serious or Rare Side Effects: - Severe neutropenia or febrile neutropenia. - QT interval prolongation on ECG. - Hepatotoxicity: significant liver injury. - Interstitial lung disease or pneumonitis. - Thrombocytopenia: low platelet count. - Severe infections requiring hospitalization.

Patients should be monitored closely for hematologic and cardiac effects.

Dose adjustment: modify dose in patients with hepatic impairment. Monitor blood counts: perform regular CBC to detect neutropenia. Assess cardiac function: obtain baseline ECG and monitor QT interval. Avoid strong CYP3A4 inhibitors: concomitant use may increase ribociclib exposure. Pregnancy: not recommended; discuss risks with a healthcare professional. Store at below 25°C: keep in the original packaging, protect from moisture and light.

Ribociclib may interact with several medications affecting its metabolism and cardiac safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase ribociclib levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - QT‑prolonging drugs (e.g., certain antiarrhythmics, haloperidol): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may modestly raise exposure. - Other QT‑prolonging agents (e.g., fluoroquinolones, certain antihistamines): require ECG monitoring. - Drugs affecting hepatic function (e.g., valproic acid): may alter metabolism. - Concomitant endocrine therapies: monitor for additive toxicities.